Dyslipidemia plays an essential role in the occurrence and development of cardiovascular diseases, and the regulation of cholesterol and triglyceride metabolism has been applied in the diagnosis, treatment and prognosis of clinical cardiovascular diseases. Following advances in methodology in recent years, low-density lipoprotein triglycerides (LDL-TG) has been identified as a potential risk factor for the development of cardiovascular disease and has some clinical significance in its diagnosis and treatment. Meanwhile, LDL-TG metabolism regulation may also be involved in the development of type 2 diabetes, chronic kidney disease, hypothyroidism and other diseases, which may improve our understanding of the prevention, control and risk assessment of clinically relevant diseases.